IL6 and COVID-19: Tocilizumab, an IL-6 inhibiting monoclonal antibody indicated for treatment of severe COVID-19 has shown safety and efficacy in two previously refractory MG patients, and safety in a third patient in a small case series (Anand et al., 2020).